The Best Stock in Utah: Myriad Genetics
We analyzed publicly traded companies based in the Beehive State to identify the best stock in Utah to buy now.
We scoured the nation to identify the best stock in every state. Myriad Genetics (symbol MYGN) is the publicly traded company we picked in Utah. The company headquarters is located in Salt Lake City.
A word of caution: Since we selected a single stock from each state (plus one from D.C), and choices in some states are sparse, a few of our picks are best suited to investors comfortable with a higher degree of risk. This is not necessarily one of our 51 favorite stocks in the entire U.S., in other words.
Myriad Genetics by the Numbers
- Headquarters: Salt Lake City
- Share price: $26.26
- Market value: $1.8 billion
- Price-earnings ratio: 26
(Prices and data are as of June 22, 2017)
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Myriad develops genetic diagnostic products. Best known for its BRACAnalysis test, which assesses a woman’s risk for developing hereditary breast and ovarian cancer, the company is seeking to expand its hereditary cancer detection business with the myRisk test, which screens 25 genes for a multitude of cancers. Myriad’s efforts to develop a host of new products, including diagnostic tests for neurological and autoimmune conditions, have eaten away at earnings recently, as has sharply declining demand for the company’s BRACAnalysis kits. But demand for the kits may have bottomed and stabilized, says Value Line analyst Nira Maharaj, and Myriad’s newer diagnostic offerings should keep the company competitive in the $700 billion diagnostics market over the next three to five years. Analysts at William Blair believe a new deal with insurer UnitedHealthcare is in the cards, potentially providing coverage for Myriad’s GeneSight test. They believe the stock will outperform the broad stock market over the next 12 months.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Ryan joined Kiplinger in the fall of 2013. He wrote and fact-checked stories that appeared in Kiplinger's Personal Finance magazine and on Kiplinger.com. He previously interned for the CBS Evening News investigative team and worked as a copy editor and features columnist at the GW Hatchet. He holds a BA in English and creative writing from George Washington University.
-
We're retired and mortgage-free, but he wants to downsize.We've paid off our mortgage, have $970K in savings and $5K each month from Social Security. Kiplinger asked wealth planners for advice.
-
How to Avoid Feeling Too Guilty to Spend in RetirementAre you living below your means in retirement because you fear not having enough to leave to your kids? Here's how to get over that.
-
Strategies for Women to Maximize Social Security BenefitsWomen often are paid less than men and live longer, so it's critical that they know their Social Security options to ensure they claim what they're entitled to.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
-
If You'd Put $1,000 Into Bank of America Stock 20 Years Ago, Here's What You'd Have TodayBank of America stock has been a massive buy-and-hold bust.
-

If You'd Put $1,000 Into Oracle Stock 20 Years Ago, Here's What You'd Have TodayORCL Oracle stock has been an outstanding buy-and-hold bet for decades.
-
If You'd Put $1,000 Into Sherwin-Williams Stock 20 Years Ago, Here's What You'd Have TodaySherwin-Williams stock has clobbered the broader market by a wide margin for a long time.